Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 December;55(6) > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 December;55(6):633-47

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

 

The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 December;55(6):633-47

IMAGING OF THERAPY RESPONSE IN ONCOLOGY 

 REVIEWS

Use of PET/CT to evaluate response to therapy in lymphoma

Zanoni L. 1, 2, Cerci J. J. 2, 3, Fanti S. 1

1 Pet Division, Nuclear Medicine Department, University Hospital Sant’Orsola-Malpighi, Bologna, Italy;
2 PET Division, Quanta-Diagnostico e Terapia, Curitiba, Brazil;
3 Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil

18F-FDG-PET is a well established standard procedure for most lymphoma subtypes. In particular the advantage of metabolic imaging stands in its strong predictivity in response. Indeed PET scan has been incorporated into revised response criteria for aggressive lymphomas and recommended to be performed at baseline and after therapy. At the same time, several ongoing clinical trials are investigating the value of treatment adaptation based on interim PET (PETi) results for Hodgkin Lymphoma (HL) and aggressive Non-Hodgkin Lymphoma (NHL). On the other hand, scientific literature provides limited detailed information regarding the numerous non aggressive NHL subtypes. Usually indolent NHL are typically less FDG avid, furthermore their long natural history and high incidence of recurrence decreases the clinical impact of a potential risk-adapted or response-adapted approach. We reviewed, from a nuclear medicine point of view and a clinical point of interest, evidence for the use of FDG-PET in monitoring early and end treatment response.

language: English


FULL TEXT  REPRINTS

top of page